Neumora Therapeutics, Inc. (NMRA)
NASDAQ: NMRA · Real-Time Price · USD
1.530
-0.030 (-1.92%)
Jun 17, 2026, 4:00 PM EDT - Market closed
Neumora Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 147.07 | 182.53 | 142.15 | 374.04 | 240.94 | 409.25 |
Short-Term Investments | - | - | 165.43 | 79.94 | 130.94 | - |
Cash & Short-Term Investments | 147.07 | 182.53 | 307.58 | 453.98 | 371.88 | 409.25 |
Cash Growth | -41.02% | -40.66% | -32.25% | 22.08% | -9.13% | 113.17% |
Other Current Assets | 6.36 | 8.01 | 6.48 | 24.3 | 16.07 | 6.36 |
Total Current Assets | 153.43 | 190.54 | 314.06 | 478.28 | 387.96 | 415.6 |
Net Property, Plant & Equipment | 0.39 | 0.46 | 2.92 | 6.86 | 10.64 | 4.04 |
Long-Term Investments | - | - | - | 9.85 | 23.51 | - |
Other Long-Term Assets | 0.05 | 0.05 | - | 1.21 | 4.13 | 9.65 |
Total Assets | 153.88 | 191.05 | 316.97 | 496.2 | 426.23 | 429.3 |
Accounts Payable | 5.06 | 3.38 | 3.31 | 0.34 | 7.15 | 1.64 |
Accrued Expenses | 24.77 | 28.79 | 24.59 | 21.26 | 11.54 | 19.1 |
Current Portion of Leases | 0.29 | 0.28 | 1.85 | 3.38 | 3.37 | 1.06 |
Other Current Liabilities | - | - | 0.13 | 0.14 | 1.64 | 1.49 |
Total Current Liabilities | 30.12 | 32.45 | 29.89 | 25.11 | 23.7 | 23.28 |
Long-Term Debt | 52.96 | 54.53 | - | - | - | - |
Long-Term Leases | 0.12 | 0.19 | - | 1.85 | 5.07 | 1 |
Other Long-Term Liabilities | - | - | 0.02 | 0.16 | 0.63 | 0.39 |
Total Long-Term Liabilities | 53.08 | 54.73 | 0.02 | 2.01 | 5.7 | 1.38 |
Total Liabilities | 83.2 | 87.18 | 29.91 | 27.12 | 29.4 | 24.66 |
Common Stock | 0.02 | 0.02 | 0.02 | 0.02 | 0 | 0 |
Additional Paid-in Capital | 1,308 | 1,288 | 1,234 | 1,173 | 21.43 | 11.38 |
Accumulated Other Comprehensive Income | - | - | 0.06 | -0.08 | -0.77 | - |
Retained Earnings | -1,238 | -1,184 | -947.22 | -703.43 | -467.51 | -336.61 |
Minority Interest | - | - | - | - | 843.69 | 729.86 |
Shareholders' Equity | 70.68 | 103.87 | 287.06 | 469.08 | -446.85 | -325.22 |
Total Liabilities & Equity | 153.88 | 191.05 | 316.97 | 496.2 | 426.23 | 429.3 |
Total Debt | 53.37 | 55.01 | 1.85 | 5.23 | 8.44 | 2.05 |
Net Cash (Debt) | 93.7 | 127.52 | 305.73 | 448.75 | 363.44 | 407.2 |
Net Cash Growth | -26.52% | -58.29% | -31.87% | 23.47% | -10.75% | 114.39% |
Net Cash Per Share | 0.56 | 0.78 | 1.92 | 6.90 | 13.36 | 18.60 |
Book Value | 70.68 | 103.87 | 287.06 | 469.08 | -446.85 | -325.22 |
Book Value Per Share | 0.42 | 0.64 | 1.80 | 7.21 | -16.42 | -14.85 |
Tangible Book Value | 70.68 | 103.87 | 287.06 | 469.08 | -446.85 | -325.22 |
Tangible Book Value Per Share | 0.42 | 0.64 | 1.80 | 7.21 | -16.42 | -14.85 |